Part 6/8:
On the medical front, a new weight loss drug, Manjaro, dubbed the "King Kong" of weight loss drugs, has been approved for limited distribution within the NHS. While the treatment has shown promise—allowing patients to lose an average of 20% of their body weight—access will initially be restricted to those with a body mass index (BMI) above 35 and related health complications. Due to overwhelming initial interest, patients will face long waits—up to a decade—for access to the drug, as only 220,000 patients will be eligible over the next three years.